XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3

License and collaboration agreement with Acadia Pharmaceuticals Inc - Additional Information (Details) - Acadia Pharmaceuticals Inc. - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Jan. 31, 2022	Sep. 30, 2024
License And Collaboration Agreement [Line Items]
Upfront Payment received	$ 60.0
Potential milestone payments receivable	$ 907.5
Remaining upfront consideration		$ 39.9

X

- Definition

License and collaboration agreement.

+ References

No definition available.

+ Details

Name:	stok_LicenseAndCollaborationAgreementLineItems
Namespace Prefix:	stok_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone payments receivable.

+ References

No definition available.

+ Details

Name:	stok_MilestonePaymentsReceivable
Namespace Prefix:	stok_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Remaining upfront consideration.

+ References

No definition available.

+ Details

Name:	stok_RemainingUpfrontConsideration
Namespace Prefix:	stok_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	stok_UpfrontPaymentReceived
Namespace Prefix:	stok_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=stok_AcadiaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: